Race reporting and representation in onychomycosis clinical trials: A systematic review

Michelle J Chang1, Yuqing Qiu2,3, Shari R Lipner3

  • 1Drexel University College of Medicine, Philadelphia, PA, USA.

Mycoses
|March 3, 2021
PubMed
Abstract

Insights

Reporting of race and ethnicity in onychomycosis clinical trials is poor, hindering generalizability. Consistent demographic data and subgroup analyses are needed to ensure treatment efficacy is understood across diverse populations.

Area of Science:

  • Dermatology
  • Clinical Trials
  • Health Disparities

Background:

  • Onychomycosis is a prevalent nail condition.
  • Diverse participant inclusion in clinical trials is crucial for generalizable efficacy data.

Purpose of the Study:

  • To systematically review race and ethnicity reporting in onychomycosis clinical trials.
  • To assess representation and treatment outcomes across different demographic groups.

Main Methods:

  • PubMed search conducted in August 2020 for onychomycosis clinical trials.
  • Analysis of primary clinical trial data, excluding post hoc studies.
  • Categorical variables compared using chi-squared and Fisher's exact tests; photos categorized by Fitzpatrick skin type.

Main Results:

  • Only 17.5% of trials reported race/ethnicity data; one trial compared subgroup efficacy.
  • Darker skin tones were rarely depicted.
  • Reporting was associated with topical treatments, US-based sites, industry funding, and post-2000 publications.

Conclusions:

  • Inconsistent reporting of participant demographics limits understanding of treatment efficacy.
  • There is a need for standardized reporting of race and ethnicity in onychomycosis trials.
  • Subgroup analyses are essential for evaluating treatment outcomes in diverse populations.

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.2K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.0K
Changes in Skin Color: Clinical Perspectives01:14

Changes in Skin Color: Clinical Perspectives

The first thing a clinician sees is the skin, so the examination of the skin should be part of any thorough physical examination. Most skin disorders are relatively benign, but a few, including melanomas, can be fatal if untreated. A couple of the more noticeable disorders, albinism and vitiligo, affect the appearance of the skin and its accessory organs.
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
2.9K
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
151
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
162
Bias in Epidemiological Studies01:29

Bias in Epidemiological Studies

Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:  
968